AlphAIAlphAI — Financial news for AI agents
tradingview.comSEP 141 min read$KMTS

KESTRA MEDICAL TECHNOLOGIES, LTD. 1Q 2027: Revenue $30.97M, EPS $(0.75) — 10-Q Summary

Kestra Medical Technologies reported Q1 2027 revenue of $30.97M, up 60% YoY, but a net loss of $(44.09)M. Diluted EPS was $(0.75). Growth was driven by increased use of its ASSURE® wearable cardiac defibrillator, with revenue primarily from Medicare, Medicaid, and private payors. The company expanded sales and marketing and improved operational efficiency.

Original reporting
tradingview.com
Published Sep 14, 2026, 9:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 7:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
KESTRA MEDICAL TECHNOLOGIES, LTD. 1Q 2027: Revenue $30.97M, EPS $(0.75) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$KMTSBearishMed
01

Why it matters

The earnings release provides fresh data for valuation models and risk assessment.

02

Market read

First‑report earnings for a micro‑cap health‑tech firm; informs short‑term trading decisions.

03

What to watch

Medicare supplier accreditation and expanding sales force may drive future profitability.

Relevance 6/10Novelty 7/10Timing: post‑market release

Background

Kestra Medical Technologies filed its Q1 2027 10‑Q, detailing financial and operational highlights.

Company-level read

Ticker impact

$KMTSBearishMedium confidence
Context

Kestra Medical reported Q1 2027 results with $30.97M revenue (up 60% YoY) and a net loss of $44.09M, EPS $(0.75).

Expected impact

Potential downside of 5‑10% as investors digest the larger loss.

Evidence & confidence

Revenue growth is strong but the loss expansion signals cost issues; market may react negatively.

Market effects

Sector

Highlights challenges in the wearable cardiac defibrillator market despite revenue growth.

Regional

Limited to U.S. healthcare investors; no broader regional effect.

Global

Minimal global impact given the company's small size.

Counterpoint

What could challenge this read

Strong revenue growth could outweigh short‑term loss, offering a buying opportunity if cost controls improve.

Key entities

  • Company
    Kestra Medical Technologies, LTD.

    Developer of the ASSURE® wearable cardiac defibrillator.

Read at source← All news

Related articles

OCT 20
$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

investing.com2 min
SEP 16
$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.

tipranks.com3 min
SEP 15
$KMTSMed

Kestra (KMTS) Q1 2027 Earnings Call Transcript

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue of $31.0M, up 60% YoY, and raised full-year guidance to $141M. Gross margin increased to 56.5%, driven by volume leverage and cost improvements. The company invested heavily in R&D and commercial expansion, resulting in a GAAP net loss of $44.1M. Management highlighted market share gains and expanded payer coverage for non-ischemic patients.

aol.com2 min
SEP 15
$KMTSMedAI 8/10

Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60%

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.

yahoo.com3 min